

Yescarta® (axicabtagene ciloleucel) – Expanded indication

- On April 1, 2022, <u>Gilead announced</u> the FDA approval of <u>Yescarta (axicabtagene ciloleucel)</u>, for the treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
 - Yescarta is also approved for treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
 - Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- In addition to LBCL, Yescarta is also approved for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
- The approval of Yescarta for the expanded indication was based on ZUMA-7, a randomized, open-label study in adult patients with relapsed or refractory LBCL after first-line chemoimmunotherapy that included rituximab and anthracycline. In total, 359 patients were randomized to receive a single infusion of Yescarta or to receive second-line standard therapy, consisting of 2 or 3 cycles of chemoimmunotherapy followed by high-dose therapy and autologous hematopoietic stem cell transplantation. The primary endpoint was event-free survival (EFS). Secondary endpoints were objective response rate (ORR) and progression-free survival (PFS).
 - Median EFS was 8.3 months and 2.0 months for the Yescarta and standard therapy arm, respectively (stratified hazard ratio [HR] 0.40, 95% CI: 0.31, 0.51; p < 0.0001).
 - The ORR was 83% and 50% for the Yescarta and standard therapy arm, respectively (difference 33, 95% CI: 23, 42; p < 0.0001).
 - Median PFS was 14.9 months and 5.0 months for the Yescarta and standard therapy arm, respectively (stratified HR 0.56, 95% CI: 0.41, 0.76).
- Yescarta carries a boxed warning for cytokine release syndrome and neurologic toxicities.
- Refer to the Yescarta drug label for completing dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.